öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÕÅÀòÄÈ
ÐÔ±ð£ºÅ®
ÈËÆøÖ¸Êý£º798

ËùÊôԺУ£ºÄþ²¨´óѧ
ËùÊôԺϵ£ºÒ½Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÁ÷Ðв¡ÓëÎÀÉúͳ¼Æѧ
Ñо¿ÁìÓò£º ÂýÐÔ²¡Á÷Ðв¡Ñ§
Ñо¿ÁìÓò£º ÂýÐÔ²¡Á÷Ðв¡Ñ§ [ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºzhanglina@nbu.edu.cn


¸öÈ˼òÊö :
ÕÅÀòÄȽÌÊÚ£¬Á÷Ðв¡ÓëÎÀÉúͳ¼Æѧ˶ʿµã¸ºÔðÈË£¬Ô¤·Àҽѧϵ¸±Ö÷ÈΣ¬ÖйúЭºÍÒ½¿Æ´óѧ˶ʿÑо¿Éú±ÏÒµ£¬ÃÀ¹úÃÜÎ÷Î÷±È´óѧҽѧÖÐÐÄ·ÃÎÊѧÕß¡£Ö÷ÒªÑо¿·½ÏòΪÂýÐÔ²¡Á÷Ðв¡Ñ§Ñо¿¡£ÔøÖ÷³Ö»ò×÷ΪÖ÷Òª¸ºÔðÈ˳е£¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢Õã½­Ê¡×ÔÈ»¿Æѧ»ù½ð¡¢Õã½­Ê¡¹«ÒæÏîÄ¿¡¢Õã½­Ê¡½ÌÓýÌüÖصãÏîÄ¿£¬Äþ²¨ÊÐ×ÔÈ»¿Æѧ»ù½ð¡¢Äþ²¨ÊÐÉç»á·¢Õ¹¹¥¹ØÏîÄ¿¡¢Äþ²¨ÊÐÔñÓÅίÍеÈÏîÄ¿10ÓàÏî¡£×÷ΪÖ÷ÒªÍê³ÉÕß»ñÊ¡¼¶¿Æ¼¼½ø²½¶þµÈ½±1Ïʡ¼¶¿Æ¼¼½ø²½½±ÈýµÈ½±1ÏÌü¼¶¿Æ¼¼½ø²½ÈýµÈ½±3Ï׫д¼°²Î±àÖø×÷6±¾£»·¢±íÂÛÎÄ60Óàƪ£¬ÆäÖÐSCIÊÕ¼20Óàƪ¡£



¿ÆÑй¤×÷ :
1.Lower ADD1 GenePromoter DNA Methylation Increases the Risk of Essential Hypertension£¬PLos One£¬2013.5.15£¬8£¨5£©.

2.Association between PCSK9 and LDLR gene polymorphisms with coronary heart disease: Case-control study and meta- analysis£¬Clinical Biochemistry£¬2013.6.01£¬46£¨9£©£º727-732

3.Association between polymorphisms of alpha-adducin gene and essential hypertension in Chinese population.£¬Bio Med Research International.£¬2013.05.19£¬2013£¨451094£©

4.Association of SCNN1B promoter methylation with essential hypertension£¬Mol Med Rep£¬2016.10.31£¬14£¨6£©£º5422-5428

5.Hypermethylation of SCNN1A gene-body increases the risk of essential hypertension£¬International Journal of Clinical and Experimental Pathology£¬2016.08.15£¬9£¨8£©£º8047-8056

6.Interactions between CYP11B2 PromoterMethylation and Smoking Increase Risk of Essential Hypertension£¬BioMed Research International£¬2016.12.19.http://dx.doi.org/10.1155/2016/**

7.Association of AGTR1 Promoter Methylation Levels with Essential Hypertension Risk: A Matched Case-Control Study£¬Cytogenetic and Genome Research£¬2015.12.12£¬147£¨2-3£©

8.The interactions between alcohol consumption and DNA methylation of the ADD1 gene promoter modulate essential hypertension susceptibility in a population-based, case¨Ccontrol study £¬Hypertension Research£¬2015.1.8£¬2015£º1-7

9.Aberrant methylation of the GCK gene body is associated with the risk of essential hypertension.Mol Med Rep. 2015. 12(2): 2390-4.

10.»·×´£ÒNA ÔÚÂýÐÔ²¡·¢²¡ÖÐ×÷ÓûúÖƵÄÑо¿½øÕ¹, ÉúÀí¿Æѧ½øÕ¹,2017 ,48 (3 ):167-172

11.Ô­·¢ÐÔ¸ßѪѹÖ÷ҪΣÏÕÒòËØÓë»ùÒò¼×»ù»¯µÄ¹ØϵÑо¿£¬ÉúÃü¿Æѧ£¬2016.12.01£¬28£¨11£©£º1353-1359

12.DNA¼×»ù»¯ÐÞÊÎÓëÔ­·¢ÐÔ¸ßѪѹ·¢²¡¹ØÁªµÄÑо¿£¬ÉúÃü¿Æѧ£¬2015.05.15£¬27£¨5£©£º590-594

13.Tm-shift»ùÒò·ÖÐÍ·½·¨ÔÚÒÅ´«Ñ§ÖеÄÓ¦Óã¬ÒÅ´«£¬2012.11.01£¬£¨11£©£º1500-1506

14.»ùÒò-»ùÒò(»·¾³)½»»¥×÷Ó÷ÖÎö·½·¨µÄ±È½Ï£¬Äþ²¨´óѧѧ±¨(Àí¹¤°æ)£¬2012.01.01£¬£¨04£©£º115-119
Õã½­Ê¡Ô¤·Àҽѧ»áÁ÷Ðв¡Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áÀíÊ£¬Õã½­Ê¡Ô¤·Àҽѧ»áÂýÐÔ²¡·À¿ØöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áÀíÊ£¬Õã½­Ê¡Ô¤·Àҽѧ»áÉ˺¦Ô¤·ÀÓë¿ØÖÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áÀíÊ£¬Äþ²¨ÊÐÔ¤·Àҽѧ»á³£ÎñÀíÊ£¬Äþ²¨ÊÐÔ¤·Àҽѧ»áÁ÷Ðв¡Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á¸±Ö÷ί¡£

1.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬**£¬ÄÆÀë×Óµ÷¿Ø»ùÒòDNA¼×»ù»¯ÓëÔ­·¢ÐÔ¸ßѪѹ¹ØÁªµÄÇ°Õ°ÐÔÑо¿£¬Ö÷³Ö

2.Õã½­Ê¡¹«Òæ¼¼ÊõÑо¿Éç»á·¢Õ¹ÏîÄ¿£¬2016C33178£¬Ô­·¢ÐÔ¸ßѪѹÕïÖÎÖÐDNA¼×»ù»¯°ÐµãµÄɸÑ¡£¬Ö÷³Ö

3.Õã½­Ê¡×ÔÈ»¿Æѧ»ù½ð£¬Y**£¬ÉöËØѪ¹Ü½ôÕÅËØϵͳ»ùÒò¶à̬ÐÔÓë¸ßѪѹµÄ¹ØÁªÑо¿£¬Ö÷³Ö

4.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÇàÄê»ù½ðÏîÄ¿£¬**£¬lncRNA¼°Æä»ùÒò¶à̬ÐÔ¶ÔÍÐÖéµ¥¿¹ÖÎÁÆÄÑÖÎÐÔRAµÄÁÆЧԤ²âÑо¿£¬²ÎÓë

5.Äþ²¨ÊÐÉç»á¹¥¹ØÏîÄ¿£¬2014C50051£¬DNA¼×»ù»¯ÔÚÔ­·¢ÐÔ¸ßѪѹÕïÖÎÖеÄÓ¦ÓÃÑо¿£¬Ö÷³Ö

6.Äþ²¨ÊÐ×ÔÈ»¿Æѧ»ù½ð£¬2011A610037£¬ÄÆÀë×ÓתÔ˵÷¿Øϵͳ»ùÒò¶à̬ÐÔÓëÑÎÃô¸ÐÐÔ¸ßѪѹµÄ¹ØÁªÑо¿£¬Ö÷³Ö

7.Õã½­Ê¡½ÌÓýÌü(Àí)¿ÆÑмƻ®£¨ÖصãÏîÄ¿£©£¬Z**£¬REN¡¢AGTºÍACE»ùÒò¶à̬ÐÔÓë¸ßѪѹµÄ¹ØÁª,Ö÷³Ö

8.¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¬**£¬ÃæÉÏÏîÄ¿ÐÂÐÍÅ©´åºÏ×÷Ò½ÁƳï×Ê»úÖƵÄÑо¿£¬²ÎÓë
1.ÎøµÄ¿¹Ö×ÁöÃâÒßµ÷½Ú×÷ÓÃÑо¿£¬Ê¡¿Æ¼¼½ø²½¶þµÈ½±£¬²ÎÓë

2.¿¹ÉúËØÓ¦ÓÃÓ벡ԭ΢Éú̬Ñо¿£¬Ê¡¿Æ¼¼½ø²½ÈýµÈ½±£¬²ÎÓë